The effectiveness and tolerability of switching Indian patients from sacubitril/valsartan, ARNI to perindopril in heart failure with reduced ejection fraction. [Efficient study]
Enregistré dans:
Auteurs principaux: | Pankaj Jariwala, Kartik Jadhav |
---|---|
Format: | article |
Langue: | EN |
Publié: |
Elsevier
2021
|
Sujets: | |
Accès en ligne: | https://doaj.org/article/c83fceb969274be9a498b3301be5ddb4 |
Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|
Documents similaires
-
Safety and effectiveness of angiotensin receptor-neprilysin inhibitors (ARNI) in patients with heart failure with preserved ejection fraction (HFPEF) – ‘ARNI-preserved’ study
par: Pankaj Jariwala, et autres
Publié: (2021) -
Tolerability Profile and Discontinuation Causes of Sacubitril/Valsartan Treatment in ‘Real-life’ Patients with Heart Failure and Reduced Ejection Fraction
par: M Rizzo, et autres
Publié: (2020) -
Rationale for and Practical Use of Sacubitril/Valsartan in the Patient’s Journey with Heart Failure and Reduced Ejection Fraction
par: Mauro Gori, et autres
Publié: (2021) -
Prescription of Sacubitril/Valsartan in Patients with Heart Failure and Reduced Ejection Fraction Attending an Outpatient Heart Failure Clinic
par: M Rizzo, et autres
Publié: (2020) -
Sacubitril-Valsartan, Clinical Benefits and Related Mechanisms of Action in Heart Failure With Reduced Ejection Fraction. A Review
par: Domingo Pascual-Figal, et autres
Publié: (2021)